Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Comment by rcash1on Feb 22, 2018 10:44am
81 Views
Post# 27601525

RE:RE:RE:We ran from 8-12,cents to $1 during the last run up.

RE:RE:RE:We ran from 8-12,cents to $1 during the last run up.
Ovechkin wrote:
If this market has taught me anything it can get parabolic really quick especially on a sales license over a cultivation license. IF, we can get our sales license within the next couple of month and release supply agreements for North Road Ventures watch out. I still think we are gunning for an export deal into Europe. Make total sense $2-$3 is in range short term IMO business model speaks for itself and can generate revenue in the short run. Not many companies with a SALES license under $2 a share. I can only think of Invictus MD. Also, I appreciate the correction on RKS investing @.40/share. Regardless, my point is that a capital corps job is to find undervalued stocks, buy-in then wait for a run-up to increase their book value. For instance RKS bought 500,000 shares of TGOD @50 cents. Small potatoes? Sure.. but a 250,000 investment now is 2 million dollars. Check out their portfolio of goods.. they clearly see something in Liberty which will bring them more book value. I STAND BY $2-$3

Almost fully agree expect now we have a few sales licensed companies trading under 2$ due to this market correction. I'll add THC and HVT to that list . There's also a few companies over 2$ with no sales license!! I'm pretty good at speculative valuations, and this will see 2$ IMO . All it takes is revenue and that's coming in the next year . 
<< Previous
Bullboard Posts
Next >>